pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

745 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1213Endpoints919BioPharma Dive354BioSpace335Fierce Biotech316onclive165raps111globenewswire health
therapy area
allOncology8159Rare Disease1937Cardiology1879Immunology1565Hematology1354Pulmonology1264Vaccines
  • Hamilton Medical issues updated use instructions for certain breathing circuit sets after serious recall
    Hamilton Medical has sent a letter to customers on May 18, 2026, advising updated use instructions for specific coaxial breathing circuit sets used with its HAMILTON-C1, HAMILTON T-1 and HAMILTON-M…
    fda medwatch · 2mo agoCRLNegative↗ source
  • Gellert Global Group recalls ALDI Fusia Kimchi & Tofu Kimbap over undeclared tuna
    Gellert Global Group of Elizabeth, NJ announced a recall of 8.1-oz packages of ALDI's Fusia Asian Inspirations Kimchi & Tofu Kimbap because they may contain undeclared tuna. The undeclared fish po…
    fda recalls · 2mo agoCRLNegative
← prev
page 24 of 30
next →
73
fda recalls71
fda medwatch63
fda press38
1262
Psychiatry & CNS889
Ophthalmology521
Pain503
Endocrinology & Metabolism495
Infectious Disease457
↗ source
  • Kao USA issues voluntary recall of select Oribe scalp shampoo lots over bacterial contamination
    Kao USA announced a voluntary recall of select lots of its Oribe Serene Scalp Densifying Shampoo in the United States and Canada after detecting the bacterium Pluralibacter gergoviae. The recall a…
    fda recalls · 2mo agoRegulatoryNegative↗ source
  • Eunha Fisheries recalls frozen halibut and flounder sashimi after undisclosed wheat, soy, sesame found in condiment packets
    On July 1, 2026, Eunha Fisheries Co., Ltd. of Busan, South Korea announced a recall of certain sliced Korean halibut and flounder sashimi products. The recall covers items that were sold in the Uni…
    fda recalls · 2mo agoRegulatoryNegative↗ source
  • La Ceiba Foods recalls Salvadoran and Mexican cottage cheese over possible Listeria contamination
    La Ceiba Foods Latin Market Inc. announced on June 26, 2026 that it is recalling its Requesón Salvadoreño (Salvadoran cottage cheese) and Requesón Mexicano (Mexican cottage cheese) products sold un…
    fda recalls · 2mo agoRegulatoryNegative↗ source
  • Preoperative intravesical mitomycin C cuts NMIBC recurrence risk by 77% over five years
    A recent study evaluated giving two doses of intravesical mitomycin C before transurethral resection of bladder tumor (TURBT) in patients with non‑muscle‑invasive bladder cancer (NMIBC). Compared…
    onclive · 4mo agoPositive readoutPositive↗ source
  • High TMB, GBD and PD-L1 Levels Linked to Better Response in Neoadjuvant Gem-iDRS or Cetrelimab Trial for Bladder Cancer
    The SunRISe-4 trial evaluated neoadjuvant gemcitabine‑based immunotherapy with or without cetrelimab in patients with muscle‑invasive bladder cancer. A biomarker sub‑analysis showed that patients…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Expert reviews real-world data on BCG retreatment after failure in non-muscle-invasive bladder cancer
    Dr Joshua J. Meeks, MD, PhD, provided an overview of a real-world study that examined the use of BCG retreatment in patients with non‑muscle‑invasive bladder cancer (NMIBC) who had previously faile…
    onclive · 4mo agoNeutral↗ source
  • Multidisciplinary quality program shown to cut side effects of androgen deprivation therapy in prostate cancer
    Dr Hafron discussed a recent study that evaluated a multidisciplinary quality initiative aimed at reducing adverse events linked to androgen deprivation therapy for prostate cancer. The program co…
    onclive · 4mo agoPositive readoutPositive↗ source
  • FDA approves trastuzumab deruxtecan for early-stage HER2-positive breast cancer
    The U.S. Food and Drug Administration has granted approval for trastuzumab deruxtecan (T‑DXd) as a treatment option in both the adjuvant and neoadjuvant settings for certain patients with early-sta…
    onclive · 4mo agoApprovalPositive↗ source
  • FDA approves adjuvant atezolizumab for MRD-positive muscle-invasive bladder cancer, says Dr. Hafron
    The U.S. Food and Drug Administration has granted approval for adjuvant atezolizumab in patients with MRD-positive muscle-invasive bladder cancer. The decision expands the use of the immunotherapy…
    onclive · 4mo agoApprovalPositive↗ source
  • Durvalumab combined with BCG cuts recurrence risk by 32% in phase 3 trial for high-risk non-muscle-invasive bladder cancer
    A phase 3 study called POTOMAC tested durvalumab together with BCG induction and maintenance against BCG alone in patients who had not previously received BCG and who have high-risk non-muscle-inva…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Darolutamide with ADT cuts death risk by half in metastatic hormone‑sensitive prostate cancer
    A recent study evaluated darolutamide combined with androgen deprivation therapy in patients with metastatic hormone‑sensitive prostate cancer. The trial reported a 50% reduction in the risk of dea…
    onclive · 4mo agoPositive readoutPositive↗ source
  • FDA approves adjuvant atezolizumab for MRD-positive muscle-invasive bladder cancer
    The U.S. Food and Drug Administration has granted approval for adjuvant atezolizumab in patients with muscle‑invasive bladder cancer who test positive for circulating tumor DNA, indicating molecula…
    onclive · 4mo agoApprovalPositive↗ source
  • Expert outlines sequencing strategies for relapsed/refractory multiple myeloma amid rise of T-cell redirecting therapies
    Dr. Diana Cirstea, a specialist in multiple myeloma, explained how treatment sequencing is evolving for patients with relapsed or refractory disease. She highlighted that the growing availability o…
    onclive · 4mo agoNeutral↗ source
  • Pembrolizumab with BCG shows 92% 6-month complete response in very high-risk T1 bladder cancer
    A clinical study evaluated the combination of pembrolizumab and bacillus Calmette-Guérin (BCG) in patients with very high-risk T1 non-muscle invasive bladder cancer who had not previously received…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Detalimogene Voraplasmid Achieves 54% Complete Response in BCG-Unresponsive Bladder Cancer
    A clinical study of detalimogene voraplasmid reported a 54% complete response rate in patients with heavily pretreated, BCG‑unresponsive non‑muscle‑invasive bladder cancer that also had carcinoma i…
    onclive · 4mo agoPositive readoutPositive↗ source
  • Prevention and personalized skin care highlighted as future direction for melanoma oncodermatology
    Dr. Beth McLellan, a dermatologist, emphasizes that preventing radiation-induced skin damage is becoming a central focus in melanoma care. She also points out the need for equitable access to scal…
    onclive · 4mo agoPositive↗ source
  • OncLive poll highlights top GI cancer abstracts and interest areas for ASCO 2026
    OncLive conducted a poll among its audience to gauge which gastrointestinal cancer abstracts are expected to generate the most interest at the upcoming ASCO Annual Meeting. The poll results identi…
    onclive · 4mo agoNeutral↗ source
  • Dr Croll reviews study linking tumor size changes on scans to pathological outcomes after neoadjuvant therapy in kidney cancer
    Dr Benjamin Croll, MD, presented findings from a recent investigation into the relationship between radiographic size changes and pathological response in renal cell carcinoma patients receiving ne…
    onclive · 4mo agoNeutral↗ source
  • Dr Garzotto reviews efficacy of aglatimagene besadenovec with valacyclovir and radiation in localized prostate cancer
    Dr Mark Garzotto presented data on a novel therapeutic approach for localized prostate cancer that combines the gene therapy agent aglatimagene besadenovec with the antiviral drug valacyclovir and…
    onclive · 4mo agoNeutral↗ source
  • GU experts poll top abstract topics for ASCO 2026 meeting
    A poll of genitourinary oncology specialists was conducted to gauge interest in upcoming ASCO 2026 abstracts. Participants used OncLive’s social media platform to nominate the abstracts they expec…
    onclive · 4mo agoNeutral↗ source
  • Roswell Park Researchers Join 2026 World Indigenous Cancer Conference
    Roswell Park Comprehensive Cancer Center staff took part in the 2026 World Indigenous Cancer Conference, a global gathering focused on cancer issues affecting Indigenous peoples. The conference br…
    onclive · 4mo agoPositive↗ source
  • OncLive launches weekly quiz on recent FDA oncology approvals
    OncLive released a weekly news quiz dated May 15, 2026, inviting readers to test their knowledge of recent oncology developments. The quiz focuses on three new FDA approvals in the oncology space…
    onclive · 4mo agoNeutral↗ source
  • Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancer
    A recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
    onclive · 4mo agoPositive readoutPositive↗ source